

## Hydroxycarbamide (Hydroxyurea) - Guidelines for treating Adults with Sickle Cell Disease

### Patient selection

The benefits of hydroxycarbamide should be discussed with all patients with SS/Sβ<sup>0</sup> to enable informed joint decision-making. It may also be useful in other types of sickle cell disease such as HbSC disease in selected patients.

### Indications:

As a standard of care, Hydroxycarbamide should be discussed with all patients with HbSS/Sβ<sup>0</sup>-thalassaemia, and the information revisited at a later date as appropriate. It can be routinely offered from 9 months of age, irrespective of clinical severity (Wang et al, 2011).

It should also be offered to patients with severe complications:

- 3 or more episodes of acute vaso-occlusive painful episodes each year, which are causing significant life;
- Recurrent or severe Acute Chest Syndrome

Other indications include:

- persistent low haemoglobin (<60g/l)
- hypoxaemia
- significant proteinuria
- patients keen to avoid blood transfusions if at all possible, those with alloantibodies or a history of severe transfusion reactions
- preoperative preparation when blood transfusions are not acceptable
- Patients changing from regular blood transfusions to maximum tolerated dose hydroxycarbamide for primary stroke prevention (see section below).
- significant cerebral vasculopathy when blood transfusions are unacceptable
- progressive cerebral vasculopathy despite adequate blood transfusions

### Parent/patient information and Consent

Patient information leaflets should be given in addition to a full discussion of risks, benefits and side effects, including dose dependent bone marrow suppression. There is no available evidence in females or males that hydroxycarbamide affects fertility. In males, the effect of hydroxycarbamide on spermatogenesis remains unclear. Most studies are case reports with few prospective studies,

### STSTN Clinical Guidelines Writing Group

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

making evidence-based counselling of the risk of developing sperm abnormalities or infertility challenging.

In view of these uncertainties it has been suggested that it is reasonable to offer post-pubertal male patients sperm analysis and cryopreservation prior to starting treatment with hydroxycarbamide .

Many patients and carers may want to think about the issues and discuss things further, a follow-up appointment to discuss things further should be offered.

### **Contacts**

Assisted Conception Unit (Guys & St Thomas') 020 7188 2300

Assisted Conception Unit (King's) Ext 020 3299 9000 Ext 35390 <mailto:kch-tr.fertility@nhs.net>

For St Georges patients please refer to: Andrology Department (Hammersmith Hospital) 020 3313 4680  
[Lia.joannou@nhs.net](mailto:Lia.joannou@nhs.net)

Hydroxycarbamide is a form of chemotherapy and informed consent is essential; discussions should be recorded in the notes but it is not necessary for the patient to sign anything.

Hydroxycarbamide at high (superpharmacological) doses is teratogenic in animals leading to abnormalities in the central nervous system, vertebral bodies, craniofacial tissue, skull and limbs in mammals. There is limited data on adverse outcomes in pregnant women, including early fetal loss or anomalies. An expert panel report from the NTP in the USA expressed concern about potential teratogenicity with hydroxycarbamide and possible harmful effects to the baby when breastfeeding (NTP-CERHR, [2008](#)). If women do conceive whilst taking hydroxycarbamide, stopping the drug should be considered in the first trimester and a detailed anomaly scan should be performed at 20 weeks gestation.

At present, until further data are available, the use of contraception is recommended for both male and female patients whilst taking hydroxycarbamide. Despite this precautionary measure, some women have become pregnant while they or their male partners were on hydroxycarbamide.

- However in men and women who have a severe disease phenotype and/or are difficult to transfuse, the risks of stopping hydroxycarbamide prenatally and for women during pregnancy may outweigh any possible risks of teratogenicity. If hydroxycarbamide is stopped prenatally and during pregnancy, consider a transfusion programme if there is a severe clinical phenotype as an alternative to hydroxycarbamide treatment. These risks should be carefully discussed with the patients to enable them to make an informed choice.

### **STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

The importance of adherence to the effectiveness of Hydroxycarbamide should be discussed. If patients miss a dose they should not take a double dose.

### **Toxicity**

- Reversible increase in skin and nail pigmentation, alopecia
- Haematological – myelosuppression – see below
- Renal
- Hepatic
- Gastrointestinal – rarely - nausea and vomiting, diarrhoea – antiemetics not usually required
- Teratogenic – Hydroxycarbamide may, theoretically harm the unborn fetus although there is no clear human evidence of this.
- Fertility in boys – some evidence of reduced fertility in males with Sickle Cell Anaemia – exact role of Hydroxycarbamide unclear
- Longterm marrow effects uncertain
- No evidence of increase in malignancy in patients with SCD taking Hydroxycarbamide.
- Drug interactions

### **Baseline investigations**

Prior to commencing hydroxycarbamide these should include:

- FBC and reticulocytes with differential count
- HbF%
- Renal function
- Hepatic function including ALT

The Clinical Nurse Specialist should be informed of all patients starting hydroxycarbamide to record them for follow up and monitoring.

### **Administration and Formulation**

Hydroxycarbamide is given orally once a day. If a dose is missed, a double dose should not be taken.

Hydroxycarbamide is available as:

- Hydroxycarbamide capsules 500mg  
Hydroxycarbamide capsules can be opened and the powder taken with a small amount of water or juice. This works well for some patients, but it should be explained that hydroxycarbamide is a form of chemotherapy and should not come into contact with skin or anybody other than the patient; this will mean washing the spoon very carefully and wiping up any spills immediately.  
Because the capsules are only available as 500mg, giving the exact calculated daily dose can be difficult, and in general it is satisfactory to give alternating day doses such as 500mg alternating with

### **STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

1g to achieve an average daily dose, although this should be explained carefully to the patient and or carers.

- SIKLOS 100mg tablets is used in paediatric practice and not usually available for adult sickle patients. When patients transition on the medication they are currently switched to the capsules.
- Where it is used SIKLOS tablets can be mixed with a small amount of water just before being taken.
- Hydroxycarbamide Liquid (100mg/ml)  
Liquid preparation is available and may be more suitable for some patients, although it has a short-shelf life, and can be difficult to obtain from local hospitals for shared-care patients. It is possible to arrange for local hospitals or pharmacies to dispense the drug, and this should be discussed with the pharmacists here.

### **Recommended Dose**

The therapeutic dose range of hydroxycarbamide is 15-35 mg/kg daily and for some indications clinical response at the lower end of the range is sufficient (Lowest Effective Dose), whilst for other indications, particularly involving cerebrovascular disease, the dose is escalated to the higher end of the range, or until myelosuppression occurs (Maximum Tolerated Dose – MTD).

Most adults start at a dose of 15mg/kg daily (to the nearest 500mg), unless there is particular concern about the risk of myelosuppression, when lower doses should be used.

### **Dose Adjustment and Monitoring**

For most patients, the dose is increased by 5mg/kg every 8-12 weeks until there is evidence of clinical benefit, which is the Lowest Effective Dose.

FBC, reticulocytes, renal and hepatic function and HbF% should be checked 2 weeks after starting, and after any dose increase, until the dose is stable and then every 8–12 weeks.

Assess clinical response and if sub-optimal, increase by 5mg/kg every 8 weeks (maximum dose 35mg/kg/day) until target ranges are reached or stopping if haematological toxicity (see below):

Target ranges:

- Neutrophils  $2.0-3.0 \times 10^9/l$
- Platelets  $\geq 100 \times 10^9/l$
- Reticulocytes  $\geq 80 \times 10^9/l$

### **STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

If cytopenias occur a dose adjustment should be made - see table below for dose adjustment for haematological toxicity. This is particularly important in patients where the aim is to increase the dose to Maximum Tolerated Dose (MTD) who are more likely to experience myelosuppression.

Neutrophils (x 10 <sup>9</sup> /l)	Reticulocytes	Platelets (x 10 <sup>9</sup> /l)	Dose Adjustment
>1.0	≥1% or ≥ 80 x 10 <sup>9</sup> /l	≥ 80	Continue current dose
< 1.0	<1% or <80 x 10 <sup>9</sup> /l (unless Hb >90g/l)	< 80	Stop treatment and recheck FBC weekly until Neutrophils >1.0 x 10 <sup>9</sup> /l platelets >80 x 10 <sup>9</sup> /l, Hb >45g/ and reticulocytes >80 x 10 <sup>9</sup> /l (unless Hb>90g/l) Restart at lower dose: reduce by either <ul style="list-style-type: none"> <li>• 2.5-5mg/kg/day or</li> <li>• 500mg/day (1 capsule) or</li> <li>• 100mg/day (SIKLOS 1 capsule)</li> </ul> Monitor FBC after 2 weeks and follow as above for dose modifications. This is the Maximum Tolerated Dose (MTD)

#### Other toxicities:

Renal: Increase in serum creatinine ≥ 50% baseline

Hepatic: > 100% increase in ALT

Stop Hydroxycarbamide, contact the family directly with instructions and arrange further tests to monitor recovery.

#### Dose adjustment to Maximum Tolerated Dose (MTD) for patients with cerebrovascular disease

For some indications, such as those involving cerebrovascular disease, the dose should be increased every 6-8 weeks by increments of 5mg/kg/day, to a maximum of 25-35mg/kg/day (maximum dose 2000mg) or until limited by myelosuppression (Maximum Tolerated Dose – MTD):

Target blood results for MTD:

Target neutrophil count 2.0-3.0 x 10<sup>9</sup>/l

Total daily dose 25-30mg/kg/day

If neutrophils < 1.0 x 10<sup>9</sup>/l, platelets <80 x 10<sup>9</sup>/l or reticulocytes <80 x 10<sup>9</sup>/l, discontinue for 2 weeks or until recovered (see above for monitoring), and restart a lower dose (usually the dose prior to the most recent dose increase). This is the Maximum Tolerated Dose.

#### STSTN Clinical Guidelines Writing Group

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

Parents should also be advised to attend hospital for assessment and urgent blood tests if they develop symptoms suggestive of sepsis, or unusual bruising or bleeding, because of the possible risk of bone marrow suppression and neutropenia or thrombocytopenia.

Inform the GP/Shared Care Hospital team/in writing of any dose adjustments and blood test results

### **Admission to Hospital**

Hydroxycarbamide therapy should be continued during hospitalizations or illness unless due to febrile neutropenia or bleeding with thrombocytopenia

### **Withdrawal of Hydroxycarbamide**

Patients should usually be treated for at least six months before deciding to stop hydroxycarbamide because of lack of benefit.

When hydroxycarbamide is associated with clinical improvement, it is typically continued lifelong.

Reference: Guidelines for the use of Hydroxycarbamide in children and adults with sickle cell disease 2018 181, 460-475

### **Contact numbers relevant to this guideline document:**

If you have any questions or concerns about issues raised in this guidance, your medicines, or other queries on your health, please speak to the staff caring for you in your local centre.

Assisted Conception Unit (Guys & St Thomas') 020 7188 2300

Assisted Conception Unit (King's) Ext 020 3299 9000 Ext 35390 <mailto:kch-tr.fertility@nhs.net>  
For St Georges patients please refer to: Andrology Department (Hammersmith Hospital) 020 3313 4680 [Lia.joannou@nhs.net](mailto:Lia.joannou@nhs.net)

Please insert your local contact details here:

Additional contacts can be found on the STSTN website ([www.ststn.co.uk](http://www.ststn.co.uk))

### **STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of

clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.

Guidelines written by the STSTN adult writing group:

Dr Sara Stuart Smith  
Dr Julia Sirkoska  
Dr Rachel Kesse-Adu

### **STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.